samedan logo
 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Quanterix to Launch High-Sensitivity Benchtop Instrument and Assays for Multiplex Biomarker Detection

Quanterix

New benchtop design and expanded assay portfolio offers researchers greater access to ultra-sensitive Simoa technology for unrivaled biomarker detection

Quanterix Corporation, a company dedicated to digitizing biomarker analysis with the goal of advancing the science of precision health, today announced it will be expanding its single molecule array, or Simoa, technology platform portfolio to include the new Quanterix SR-Plex benchtop instrument. In the same way that the fully automated HD-1 Analyzer offers detection and measurement of biomarkers with unprecedented sensitivity, the SR-Plex will use single molecule measurements to assess previously undetectable proteins and can significantly reduce sample volume requirements when compared to alternative approaches, all in a benchtop format that can be easily integrated with existing automation platforms. The first unveiling of the SR-Plex will happen today at the Next Generation Dx Summit in Washington, D.C. “We are approaching an intersection of the digital health revolution and life science research. From high-throughput studies with our HD-1 Analyzer to the potential for blood-based, point-ofcare tools, the unrivaled sensitivity of the Simoa technology helps pharma, academia and other research labs look at the most important biological information in life,” said Kevin Hrusovsky, Executive Chairman and Chief Executive Officer at Quanterix. “In addition to a smaller instrument footprint, the SR-Plex has been optimized for increased multiplexing capabilities, making it an easy to use and economical option for high-sensitivity biomarker analysis, whether proteins or nucleic acids.” The SR-Plex will be part of a complete solution including a menu of more than 70 ultra-sensitive protein detection assays, as well as a new series of multiplex assays for critical biomarkers, including the first six-plex Simoa assay for quantitative measurement of elusive inflammatory biomarkers in the blood. “We are particularly excited that the SR-Plex has the potential to lead to advances in the application of circulating biomarkers, especially for cancer detection and treatment. Despite recent innovations in genomic and proteomic technologies, there has been little advancement in immunological biomarker tests,” continued Hrusovsky. “Simoa’s multiplexing capabilities and digital sensitivity provides, for the first time, the ability to measure circulating clinically relevant concentrations of immunological mediators, exosomes and miRNA in a single benchtop instrument.” More than 145 studies using the Simoa technology have been published in peer-reviewed journals. This research spans several therapeutic areas such as oncology, neurology, cardiology, inflammation and infectious disease and has shown that Simoa has the potential to detect biomarkers in the subclinical state, which is valuable for the monitoring of neurodegeneration in diseases like Alzheimer’s disease and multiple sclerosis.Myriad RBM, Inc., the world’s leading multiplexed immunoassay testing laboratory, will begin using the SR-Plex as part of an early-access program: “We’ve previously worked with the HD-1 Analyzer and have been consistently impressed with the flexibility of the Simoa technology and the depth that this approach provides. It allows us to detect biomarkers we couldn’t previously see with other approaches. Now, as a benchtop instrument that offers multiplexing capabilities, we can optimize our in-house laboratory robotics and liquid handlers to gain significant economies of scale, including sample preservation and throughput, which helps with our bottom line costs,” said Ralph McDade, Ph.D., President at Myriad. The SR-Plex benchtop instrument will be on display for the first time at the Next Generation Dx Summit in Washington, D.C., August 15-17, 2017. On August 15 at 1:00 p.m. ET, Kevin Hrusovsky will lead a luncheon presentation titled “Convergence of Next Generation Digital Health and Biomarker Technologies is Enabling a Transformation to Asymptomatic Medicine and Precision Health”. Mr. Hrusovsky will also join leaders from bioMérieux and Novarum to participate in a keynote Technology Panel on August 16 at 12:15 p.m. ET titled “Disruptive Technologies in Lab Medicine”. Quanterix will initiate an early-access program for the SR-Plex beginning in Q4 2017 and expects full availability of the product in Q1 2018.The SR-Plex is for research use only and not for use in diagnostic procedures. More information about the Quanterix SR-Plex and available assays can be found at is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. Simoa™, Simoa HD-1™, SR-Plex™, and HD-1 Analyzer™ are trademarks of Quanterix Corporation.Maurissa Messier c. 908-208-9254
phone 617-301-9400
email info@quanterix.com
web www.quanterix.com
email 113 Hartwell Ave, Lexington, MA 02421
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Avacta and Leeds University awarded £3.8m Medical Research Council funding to develop new diagnostic tests


More info >>


White Papers

Generating Scientific Insights by Deep Collaboration - Bridging the Big Data Divide Between Clinical and Research

BioFortis

Translational research, biomarker discovery, clinical studies and even biobanking have become increasingly data intensive.  However, generating scientific insights from such disparate “big” data sources across multiple domains is a challenge for both researchers and the informaticians that support them. Download our Deep Collaboration Whitepaper and and learn how to bridge the clinical and research divide to better explore your biomarker based trials.
More info >>

Industry Events

Pharma and Device Packaging and Labeling West Coast 2017

28-29 November 2017, Burlingame, California

Following a very successful launch year, we are thrilled to announce that Pharma and Device Packaging and Labeling will be returning to the West Coast for our 2nd annual event.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement